Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Sells $77,200.00 in Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 40,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $1.93, for a total value of $77,200.00. Following the sale, the chairman now owns 1,331,543 shares in the company, valued at $2,569,877.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Neil Desai also recently made the following trade(s):

• On Monday, April 1st, Neil Desai sold 17,772 shares of Aadi Bioscience stock. The shares were sold at an average price of $2.31, for a total value of $41,053.32.
• On Monday, March 4th, Neil Desai sold 14,964 shares of Aadi Bioscience stock. The shares were sold at an average price of $2.10, for a total value of $31,424.40.
• On Friday, March 1st, Neil Desai sold 27,036 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.97, for a total value of $53,260.92.
• On Thursday, February 1st, Neil Desai sold 42,000 shares of Aadi Bioscience stock. The stock was sold at an average price of $1.74, for a total value of $73,080.00.

Aadi Bioscience Stock Up 5.0 %

Aadi Bioscience stock opened at $2.12 on Friday. Aadi Bioscience, Inc. has a 52 week low of $1.55 and a 52 week high of $8.60. The business has a 50-day simple moving average of $2.06 and a 200 day simple moving average of $2.77. The stock has a market cap of $52.05 million, a price-to-earnings ratio of -0.87 and a beta of 0.64.

Aadi Bioscience (NASDAQ:AADI) last posted its earnings results on Wednesday, March 13th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.07. Aadi Bioscience had a negative return on equity of 52.53% and a negative net margin of 270.04%. The business had revenue of $6.33 million during the quarter, compared to analysts’ expectations of $6.46 million. On average, research analysts anticipate that Aadi Bioscience, Inc. will post -2.47 earnings per share for the current year.

Hedge Funds Weigh In On Aadi Bioscience

An institutional investor recently raised its position in Aadi Bioscience stock. TD Asset Management Inc lifted its position in Aadi Bioscience, Inc. (NASDAQ:AADI) by 100.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,166 shares of the company’s stock after purchasing an additional 24,083 shares during the quarter. TD Asset Management Inc owned 0.20% of Aadi Bioscience worth $233,000 at the end of the most recent quarter. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.